Anti-Mouse CD1d (CD1.1) – Purified in vivo GOLD™ Functional Grade

Clone 20H2 is a monoclonal antibody directed against mouse CD1d (CD1.1), a molecule involved in lipid antigen presentation to NKT (natural killer T) cells. The common in vivo applications of clone 20H2 in mice include:

• In vivo functional assays to study the role of CD1d in immune responses, often by blocking or neutralizing CD1d function on mouse cells.
• Pathway analysis of CD1d-mediated antigen presentation and NKT cell activation, to understand how CD1d affects various biological and immunological pathways in vivo.
• Bioanalytical pharmacokinetic (PK) and anti-drug antibody (ADA) assays using clone 20H2 as a research tool for monitoring the presence or effects of CD1d-targeted interventions in mice.

These in vivo applications are foundational in immunological research, especially for dissecting NKT cell biology, autoimmunity, infections, and tumor immunology where the mouse CD1d pathway plays a functional role. Some vendors specifically market clone 20H2 as an in vivo-grade reagent, suggesting it is optimized for injection into live mice for these experimental purposes.

Commonly used antibodies or proteins that are paired with 20H2 (anti-mouse CD1d/CD1.1) in the literature depend on the immunological context, as CD1d is primarily involved in antigen presentation to NKT cells. Frequently, researchers studying CD1d or using 20H2 include additional antibodies or proteins to characterize immune cell subsets and pathways.

Key antibodies and proteins commonly used with 20H2 in immunological studies:

• TCRβ (T Cell Receptor beta chain): Used to identify and gate total T cells.
• NK1.1: Common marker for natural killer (NK) and NKT cells in mice; often used to distinguish NKT (CD1d tetramer+NK1.1+) populations.
• CD3: Pan-T cell marker; combined with 20H2 to identify T cell subpopulations involved in or affected by CD1d restriction.
• CD4 and CD8: Markers for T cell subsets; may be used to further categorize NKT cell populations or investigate CD1d-restricted responses among conventional T cells.
• CD19 or B220: B cell markers to distinguish B cells in mixed splenocyte or lymphocyte suspensions.
• CD11b, CD11c, F4/80: Myeloid lineage markers, sometimes included to analyze antigen presenting cells expressing CD1d or to exclude non-lymphoid populations.
• α-GalCer/CD1d tetramers: These reagents combine glycolipid antigen α-Galactosylceramide with CD1d for direct staining of invariant NKT (iNKT) cells; often used in combination with 20H2 for mechanistic or functional studies of the CD1d/NKT axis.

Reporter and assay proteins:
When doing functional readouts, researchers may use antibodies/proteins against:

• Cytokines (e.g., IFN-γ, IL-4, IL-17), to assess cytokine production by CD1d-restricted cells in response to antigen presentation.
• Housekeeping controls (e.g., β-actin, GAPDH) in western blotting or qPCR, though not specific to CD1d studies, are common for normalization.

Secondary antibodies:
Experimental protocols typically include species- and isotype-specific secondary antibodies for detection in flow cytometry, Western blotting, or immunohistochemistry.

Summary Table of Common Partners for 20H2 (anti-CD1d/CD1.1):

Use of 20H2 is rarely standalone; characterization of immune populations and functional assays almost always require co-staining or co-assaying with the above reagents to provide meaningful biological insights.

Clone 20H2 is cited in scientific literature as a monoclonal antibody targeting mouse CD1d, widely used for immunological analyses involving antigen-presenting glycoprotein CD1d1 in mice.

Key findings supported by citations involving clone 20H2 include:

• Specificity: Clone 20H2 is frequently referenced for its ability to specifically bind to mouse CD1d, confirming its utility in experiments where accurate identification of the CD1d molecule is essential.
• Experimental Applications: Studies using clone 20H2 predominantly focus on flow cytometry and cell sorting techniques to analyze CD1d expression on various mouse cell populations.
• Role in Immunology: The antibody is commonly deployed in research exploring the function of CD1d in antigen presentation, NKT cell biology, and related mouse immunological models.

Most scientific citations describe clone 20H2 as a reliable tool for dissecting mouse CD1d-mediated immune processes, often in conjunction with other clones or antibody controls for comparative or validation purposes. There are no prominently reported controversies or citation biases surrounding clone 20H2 in the retrieved literature.

Specific published dosing regimens for clone 20H2 across different mouse models are not included in the provided search results, and as such, no direct comparison of its use in diverse models is possible from the available literature. If you are referring to an antibody or antibody drug conjugate (ADC), guidelines for in vivo dosing are generally determined by factors such as the target antigen, mouse strain, disease model, and intended experimental outcome.

Essential context:

• General dosing recommendations for in vivo antibodies (not clone-specific) in mouse models typically range from 100–500 μg per mouse per injection, administered via intraperitoneal or intravenous routes, and repeated every 2–4 days, depending on the antibody and application.
• Dosing schedules often vary with experimental aims—e.g., cancer models might use higher and more frequent doses for effective checkpoint blockade, while immune modulation studies might use lower or less frequent dosing.
• Some regimens use loading doses—higher initial injections—to rapidly achieve effective serum concentrations in disease models, while others rely on steady, repeated dosing.
• Protocols often require pilot experiments to optimize clone-specific pharmacokinetics and efficacy in each mouse model.

Additional relevant information:

• Because different mouse strains, tumor models, or disease conditions can influence antibody distribution and pharmacodynamics, dosing must be tailored for each context.
• If clone 20H2's specific use is novel or less well published, standard practice is to start within established dosing ranges cited above and adjust based on observed efficacy and toxicity.

There is no evidence in these results of published comparative dosing regimens for clone 20H2 by mouse model. For precise dosing, consult the manufacturer, recent publications, or validated antibody dosing guides tailored to the clone and disease context.